Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by DonEgonon Sep 23, 2012 2:55pm
190 Views
Post# 20404502

RE: RE: RE: RE: How come?

RE: RE: RE: RE: How come?

Hey digger,

I do not think that the increase to 200k/pa is due to the Goldfields project. The new ressource should not only be used to replace the Black Fox open pit mine.

When he company started the Phase 1 mill expansion of Black Fox (from 2000 to 2200), they announced also the plan to expand mill capacity to 3500 tpd.

https://www.snl.com/IRWebLinkX/file.aspx?IID=4288058&FID=11381228

"The Company has commissioned a Phase 2 mill expansion plan, that if implemented in the future, would increase processing capacity to 3,500 tonnes per day and would include replacement of the existing crushing plant with a semi-autogenous grinding (SAG) mill. "

"A decision to proceed with the Phase 2 expansion will facilitate rapid development scenarios from new discoveries within the Black Fox Complex. In conjunction with the Phase 1 mill expansion and continuing exploration success from the Black Fox Complex, Brigus has deferred a production decision on its Saskatchewan Goldfields property as it considers various expansion scenarios at the Black Fox Complex and involving an expanded Black Fox Mill."

Bullboard Posts